Publications by authors named "N Hanai"
Introduction: Chemoradiation therapy (CRT) with concurrent high-dose cisplatin (CDDP) is one of the standard treatment options for locally advanced head and neck cancer. Since the indications specific to the older population have not been reported, we conducted a multicenter survey on the indications.
Methods: In April and May 2023, a questionnaire survey was emailed to all institutions belonging to the JCOG-HNCSG, consisting of 37 institutions.
Paclitaxel plus cetuximab versus nivolumab for patients with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis.
Int J Clin Oncol
January 2025
Background: Nivolumab is the standard treatment for platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma (R/M-HNSCC). Several studies have reported the efficacy of paclitaxel plus cetuximab (PC) combination therapy in this patient population.
Methods: We conducted a retrospective analysis of patients with platinum-refractory R/M-HNSCC treated with nivolumab or PC at our institution between January 2015 and March 2022.
Basal cell adenomas (BCAs) are benign epithelial tumors of the salivary gland, characterized by the proliferation of basaloid and luminal cells. In addition, a distinctive spindle cell stroma, that is immunohistochemically-positive for S100, is often observed in BCAs. Based on the ultrastructural findings, the S100-positive stroma was presumed to originate from neoplastic myoepithelial cells.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to identify prognostic factors from neck dissections in patients with regional recurrent or residual head and neck cancer, focusing on continuous variables related to pathologic lymph nodes.
- Researchers analyzed data from 184 patients with head and neck squamous cell carcinomas, evaluating lymph node density (LND) and log odds of positive lymph nodes (LODDS) to estimate survival outcomes.
- Findings revealed that higher LND (≥ 0.14) is significantly associated with poorer survival outcomes, indicating it as a negative prognostic factor after salvage neck dissection.
Article Synopsis
- Phase III KEYNOTE-048 study compared the effectiveness of pembrolizumab, pembrolizumab-chemotherapy, and cetuximab-chemotherapy (EXTREME) in Japanese patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) over 5 years.
- Results showed that patients receiving pembrolizumab had significantly higher 5-year overall survival rates compared to those on EXTREME, indicating its potential as a better first-line treatment option.
- Pembrolizumab-chemotherapy also demonstrated durability, but its survival rates were less consistent compared to pembrolizumab alone in the same population.